Was the GlaxoSmithKline FCPA resolution a missed opportunity?
Tom Fox questions whether U.S. regulators missed a chance to illustrate how they would give credit for anti-corruption prosecutions done by other governments in the case of GlaxoSmithKline’s China subsidiary’s recent FCPA resolution.
Related articles
-
ArticleU.K. enforcement appetite over off-channel comms grows as U.S. wanes
The U.K’.s financial regulator has given a strong indication that financial firms’ use of unauthorized devices and apps is under scrutiny and that policies around off-channel communications need to be tightened up.
-
WebcastSept 23 | Decoding DOJ’s Recent Guidance on FCPA Enforcement
Join this timely and practical webinar as we break down the DOJ’s latest FCPA guidance and explore what these developments mean for compliance programs in the real world.
-
ArticleProsecutions of bribery, health fraud and market tampering are DOJ top priorities
Serious bribery, health care fraud and crimes that threaten U.S. investors are top enforcement priorities of the Trump Department of Justice, (DOJ), according to the acting head of the Department of Justice’s Criminal Division.